Camrelizumab and Apatinib for Liver Cancer Treatment
Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma
Recruiting
Phase 3
Interventional Study
Hepatocellular Carcinoma
Immunotherapy
Preoperative
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 130 (estimated)
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University · Other
Who this trial is looking for
This trial is looking for adults with a type of liver cancer called hepatocellular carcinoma. Participants will receive a combination of two medications before and after surgery to see if it helps improve their recovery and survival rate.
Are You a Good Fit for This Trial?
You may be able to join if
- I am at least 18 years old.
- I have been diagnosed with hepatocellular carcinoma.
- I have a specific stage of cancer that qualifies for surgery.
- I have a Child-Pugh score of A (6 points or less).
- My ECOG performance status score is 0 or 1.
You may not be able to join if
- I have another type of liver cancer or another active cancer.
- I currently have interstitial pneumonia or lung disease.
- I have an active autoimmune disease or a history of it.
- I have an active infection or a fever over 38.5°C before the trial.
- I have immune deficiencies, such as being HIV positive.
- I am allergic to monoclonal antibodies or related medications.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Hepatectomy is a curable and effective method. However, the recurrence rate is as high as 50%\~70% in 5 years after surgery. Perioperative treatment with immunotherapy combined with target therapy is expected to improve the patient's prognosis. This study aims to evaluate the efficacy, safety and tolerability of camrelizumab c…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Volunteer to participate in this study and sign an informed consent form.
* Age ≥18 years old, no gender limit.
* Hepatocellular carcinoma confirmed by histopathology, cytology or imaging.
* CNLC stage Ib (single tumor with diameter ≥8 cm)/IIa/IIb/IIIa hepatocellular carcinoma…
Contacts